Glucose Tolerance Clinical Trial
Official title:
Modulating Glucose Tolerance With Dietary Tyrosine
Verified date | April 2021 |
Source | Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Metabolic or Bariatric surgery is an effective treatment for type 2 diabetes mellitus (T2DM) diabetes associated with obesity. There remain some questions about the biochemical mechanism that drive how these surgeries work to reverse hyperglycemia. In the proposed human studies, the investigators will test the hypothesis that the amino acid tyrosine is a key metabolite in regulating blood sugar levels and that manipulation of the amount tyrosine supplied by nutrition is able to achieve some of the metabolic benefits seen in the early post-surgical period following bariatric surgery. The central hypothesis is that that the tyrosine content of the meal challenge affects post-prandial intestinal and plasma dopamine and levodopa and L-3,4-dihydroxyphenylalanine (L-DOPA) levels, which, in turn, impact β-cell insulin secretion and glucose excursions. The investigators now propose to characterize the possible effects of manipulating dopamine and L-DOPA levels in the gut and plasma on glucose tolerance, insulin secretion, and insulin sensitivity in healthy volunteers with a range of body mass indexes (BMIs).
Status | Completed |
Enrollment | 10 |
Est. completion date | January 24, 2020 |
Est. primary completion date | January 24, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | i. Inclusion Criteria 1. Capable of giving written as well as oral informed consent. 2. A fasting plasma glucose level (FPG) < 126 mg/dL (< 7.0 mmol/L) and an Hb1ac in the 5.7-6.4 % range. 3. BMI in the range of 18-45 kg/m2. 4. Normal Complete blood count (CBC), renal and liver function tests. ii. Exclusion Criteria: 1. Any diabetes medication within previous three (3) months. 2. Fasting plasma Glucose (FPG) >126 mg/dl or HbA1c > 6.4% 3. Current use (or within 6 months) of antipsychotic, anti-anxiety, or antidepressant medications (e.g. monoamine oxidase (MAO) inhibitors, 5-Hydroxytryptophan (5HT) inhibitors, tricyclic antidepressants, L-DOPA), reserpine, ß-2-receptor agonists (e.g., terbutaline), steroids, weight loss medication, anticoagulant medication, over-the-counter nutritional supplements other than standard vitamin and mineral supplements 4. History of Phenylketonuria or other inherited disorders of amino acid metabolism. 5. History of movement disorder such as Parkinson's disease or Huntington's disease 6. Cardiovascular, renal, pulmonary, gastrointestinal, migraines or other medical conditions deemed significant by investigators 7. History of/ or psychiatric illness such as major depression, bipolar disease, anxiety or schizophrenia. 8. History of bariatric surgery with the exception of gastric band if the band has been removed 9. Female of child-bearing age, currently pregnant, breastfeeding or not using a form of birth control. 10. Previous or current use of cocaine, methamphetamine, ecstasy (3-4 methylenedioxymethamphetamine (MDMA)) 11. Current daily intake of caffeine >500 mg/day (>4-5 cups of coffee; >10 12-oz cans of soda) 12. Consumption of more than 1 alcoholic drink per day or smoking more than 5 cigarettes/day. 13. Systolic Blood Pressure (SBP) > 150 mmHg; Diastolic Blood Pressure (DBP) > 100 mmHg. 14. Recent history (in the past three months) of more than a 3% gain or loss in body wt. 15. Difficulty in swallowing capsules. 16. Concurrent use of antacids or proton pump inhibitors (e.g.,Prilosec Prevacid, dexilant, Aciphex, Protonix, Nexium, Vimovo, Zegerid) |
Country | Name | City | State |
---|---|---|---|
United States | Columbia University Irving Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Columbia University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Korner J, Cline GW, Slifstein M, Barba P, Rayat GR, Febres G, Leibel RL, Maffei A, Harris PE. A role for foregut tyrosine metabolism in glucose tolerance. Mol Metab. 2019 May;23:37-50. doi: 10.1016/j.molmet.2019.02.008. Epub 2019 Feb 27. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Whole blood glucose level | Glucose concentration versus time profile following glucose challenge define glucose tolerance | Up to 120 minutes from baseline | |
Primary | Plasma insulin concentration | Plasma insulin concentration versus time profile following glucose challenge define glucose tolerance | Up to 120 minutes from baseline | |
Primary | Plasma dopamine concentration | Plasma dopamine concentration versus time profile following glucose challenge may affect glucose tolerance | Up to 120 minutes from baseline | |
Primary | Plasma L-DOPA concentration | Plasma L-DOPA concentration versus time profile following glucose challenge may affect glucose tolerance | Up to 120 minutes from baseline | |
Primary | L-tyrosine concentration | Plasma L-tyrosine concentration versus time profile following glucose challenge may affect glucose tolerance | Up to 120 minutes from baseline | |
Primary | Plasma glucagon concentration | Plasma glucagon concentration versus time profile following glucose challenge impacts glucose tolerance | Up to 120 minutes from baseline | |
Primary | Plasma GLP-1 concentration | Plasma GLP-1 concentration versus time profile following glucose challenge impacts glucose tolerance | Up to 120 minutes from baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02913079 -
The Acute Impact of Sit-stand Desks on Post-meal Blood Sugar Levels
|
N/A | |
Completed |
NCT02065271 -
Herbal Preparation and Glucose Homeostasis
|
N/A | |
Completed |
NCT00985270 -
Pregnane X Receptor (PXR) Agonist Rifampicin Effects on Glucose, Lipid and Hormone Homeostasis
|
Phase 4 | |
Completed |
NCT01705639 -
Melatonin and Glucose Tolerance Among Individuals With a Variant of the MTNR1B Gene
|
Phase 3 | |
Active, not recruiting |
NCT01798030 -
Vitamin D Retrospective Study and Role With Disease
|
||
Completed |
NCT03423381 -
Dietary Fibre and Metabolic Benefits
|
N/A | |
Completed |
NCT06193291 -
Effect of Hot Water Immersion on Heart Rate Variability and Glucose
|
N/A | |
Recruiting |
NCT05300256 -
Peripheral Heating and Glucose Tolerance
|
N/A | |
Completed |
NCT04439630 -
Effects of Nopal Fractions on Postprandial Glucose Regulation and Appetite Variables in Healthy Humans
|
N/A | |
Completed |
NCT03714438 -
Effect of Medicago Sativa on Oral Glucose Tolerance in Healthy Adults
|
Phase 2 | |
Completed |
NCT00628524 -
Homburg Cream & Sugar Study
|
N/A | |
Recruiting |
NCT03725969 -
Effect of Camel Milk on Insulin and Incretin Response
|
N/A | |
Recruiting |
NCT04966299 -
Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents
|
N/A | |
Completed |
NCT04904133 -
Effects of Low/No Calorie Sweeteners on Glucose Tolerance
|
N/A |